To systematically evaluate the efficacy and safety of Qili Qiangxin Capsules(QLQX) in the adjuvant treatment of dilated cardiomyopathy.Methods:The randomized controlled trials(RCTs) on QLQX in the treatment of dilated cardiomyopathy published from database inception to August 2020 were retrieved from Cochrane Library，PubMed，EMBase，CNKI，CSPD，CCD，and CBM.The included RCTs were assessed for risks of bias，followed by Meta-analysis by RevMan 5.3.Results:Sixteen articles were included，with 1 812 subjects involved.As revealed by Meta-analysis，QLQX combined with western medicine further improved the cardiac function(RR=0.35，95%CI 0.25 to 0.48，P<0.000 01)，reduced the level of BNP(MD=-0.09，95%CI -0.13 to -0.05，P<0.000 1］，increased LVEF(MD=5.26，95%CI 3.69 to 6.82，P<0.000 01) and 6MWT(MD=43.43，95%CI 39.78 to 47.08，P<0.000 01)，and reduced LVEDD(MD=-4.48，95%CI -5.85 to -3.11，P<0.000 01) and LVESD(MD=-4.40，95%CI -5.30 to -3.49，P<0.000 01).Subgroup analysis suggested that the course of treatment might be related to the increase in LVEF and the reduction of LVESD.GRADE system showed the efficacy of cardiac function was of low quality，BNP，LVEF，LVEDD，LVESD，and 6MWT were of very low quality.Conclusion:QLQX combined with western medicine is safe and effective in the treatment of dilated cardiomyopathy.It can significantly increase cardiac function，improve relevant inspection indexes，and further improve clinical symptoms.Due to the limited quality of the included RCTs，the above conclusion needs to be further verified by higher-level RCTs.